";s:4:"text";s:4696:" The drug can also increase metformin concentrations and consequently monitoring is recommended in case dose adjustment is required.
Unable to load your delegates due to an error
Meanwhile other INIs with a similar mechanism of action such as elvitegravir and dolutegravir have been clinically evaluated. It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure. Increasing the dose of dolutegravir (50 mg/12 h) is only recommended when administered with efavirenz, nevirapine, fosamprenavir/r, tipranavir/r, rifampicin, carbamazepine, phenytoin and phenobarbital. Dolutegravir should be administered 2 h before or 6 h after antacids or products with polyvalent cations. 2014 May;34(5):506-20. doi: 10.1002/phar.1386. The company is engaged in developing new HIV medicines and supporting people and communities living with HIV.Other drugs approved for the treatment of HIV-1 include Sustiva (efavirenz) developed by Bristol-Myers Squibb (BMS) and DuPont Merck, Stribild manufactured by Gilead Sciences and Japan Tobacco (JT), Kesimpta® (ofatumumab) is the first and only self-administered, targeted B-cell therapy indicated for the treatment of patients with relapsing multiple…VILTEPSO™ (viltolarsen) is an antisense oligonucleotide drug indicated to treat Duchenne muscular dystrophy (DMD), a rare genetic disorder, in patients…OLINVYK™ (oliceridine) is a new chemical agent indicated for the treatment of acute pain in adults for whom the available…Evrysdi™ (risdiplam) is the first and only oral medication indicated for the treatment of spinal muscular atrophy (SMA) in patients…Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here Triumeq is also approved in Canada and is being reviewed for approval by regulatory authorities in Australia and Brazil.The HIV infection is caused by a virus which affects the immune system and leads to severe lifelong illness due to its long incubation period. This site needs JavaScript to work properly.
Epub 2013 Dec 18.Clin Pharmacokinet. Dolutegravir is a second-generation integrase strand transfer inhibitor (INSTI), whose potential and binding half-life in the integrase are far superior to those of raltegravir and elvitegravir, conferring it with unique characteristics in terms of its genetic barrier to resistance and activity against viruses with one or more mutations in the integrase. Secondary outcome measures included safety and tolerability parameters as assessed by change from baseline in 12-lead ECG and vital signs.FDA and EU approvals for Triumeq were based on data obtained from two pivotal Phase III clinical studies.
Dolutegravir is indicated in combination with other antiretroviral agents for the treatment of HIV in adults and children 12 years and older weighing at least 40kg. 2014 May;34(5):506-20. doi: 10.1002/phar.1386.
COVID-19 is an emerging, rapidly evolving situation. COVID-19 is an emerging, rapidly evolving situation. The pharmacokinetic properties of dolutegravir allow once-daily dosing (50 mg), with or without food, maintaining concentrations far above those effective against wild-type viruses. Mechanism of Action. Q148H/G140S amino acid substitutions in IN that pervade clinical INSTI failure perturb optimal magnesium ion coordination in the enzyme active site.
Triumeq consists of three active substances: dolutegravir, abacavir and lamivudine. In summary, dolutegravir has excellent pharmacokinetic and drug interaction profiles.
Ann Pharmacother. Side effects requiring immediate medical attention.
Integrase strand transfer inhibitor (INSTI); inhibits catalytic activity of HIV-1 integrase, an HIV encoded enzyme required for viral replication. Coadministration of dolutegravir with etravirine is not recommended without a protease inhibitor or with Hypericum perforatum.